U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Fig. 3

Fig. 3. From: AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.

Trial schema. Trial entry, randomisation and treatment. ART anti-retroviral therapy, EFA early fungicidal activity, SAE serious adverse event

Mooketsi Molefi, et al. Trials. 2015;16:276.
2.
Fig. 2

Fig. 2. From: AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.

Early fungicidal activity and mortality. The left hand panel shows the crude mortality rate (per person year) calculated over the first 2 weeks of treatment according to early fungicidal activity (EFA) in the 450 patients of the 501 anti-retroviral therapy (ART)-naive patients recruited in the studies listed in Reference 2 with slope (EFA) data. Patients have been stratified by EFA, with the slowest rate of clearance being 0–0.1 log10CFU/ml/day (equating to a 0 to 0.1 log drop in colony-forming units (CFU) per ml of cerebrospinal fluid (CSF) per day) and the highest rate of clearance being 0.5+ (equating to a half-log10 drop or more in CFU counts/ml of CSF per day). The right hand panel shows Kaplan Meier survival curves for the 501 ART-naive patients recruited into the studies listed in Reference 2 over the first 10 weeks of treatment, stratified by EFA. The slowest rates of clearance are indicated by the solid black line (EFA 0–0.1 decline in log10CFU/ml/day) and the most rapid rates of clearance are indicated by the small dotted line (EFA >0.3 decline in log10CFU/ml/day)

Mooketsi Molefi, et al. Trials. 2015;16:276.
3.
Fig. 1

Fig. 1. From: AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.

The effect of various regimens of amphotericin B for experimental cryptococcal meningoencephalitis. Amphotericin B deoxycholate 1 mg/kg was administered daily (b), every third day (c), as an abbreviated regimen for 3 consecutive days (d) and once (e). The solid arrows show the time of drug administration. The data in a-e represent the time course of infection in the cerebrospinal fluid (CSF). Each line represents the fungal burden in an individual rabbit. f shows the fungal density in the cerebrum at the end of the experiment. Each bar represents the mean fungal density ± standard error of the mean. There is no statistically significant difference in the cerebral fungal density of rabbits receiving daily therapy versus those receiving an abbreviated regimen of 1 mg/kg at 48, 72 and 96 h relative to inoculation: *p = 1.00 (not significant), **p = 0.006, ***p = <0.001, ****p = <0.001, *****p = 1.00 (not significant). CFU, colony-forming units. From Livermore J, Howard SJ, Sharp AD, et al. Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. MBio 2013; 5 (1): e00725-13. With permission

Mooketsi Molefi, et al. Trials. 2015;16:276.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center